New treatment options for renal cell carcinoma-efficacy and safety of immune checkpoint inhibitors

研究成果: Contribution to journalReview article査読

抄録

In addition to chemotherapy for advanced renal cell carcinoma (RCC), molecular targeted drugs such as tyrosine kinase inhibitors (TKI) and mTOR inhibitors have been clinically introduced, and they have contributed to improved progression free survival (PFS) and overall survival (OS). However, complete response over a long period are rarely obtained with these drugs, and there are many cases of recurrence and progression. The anti-PD-1 antibody nivolumab, an immune checkpoint inhibitor, has approved for the indication of "Unresectable or metastatic RCC" in Japan, based on the phase III study results for advanced RCC with previous TKI treatment. The nivolumab response indicates the possibility of a sustained treatment effect for a long period of time, but also suggests the tendency to take time to develop the effect. Regarding safety, immune-related adverse events (irAEs) with a profile that may be different from those of conventional drugs, and in addition to fully understanding these features, we need to be familiar with how to manage irAEs,.

本文言語英語
ページ(範囲)667-673
ページ数7
ジャーナルJapanese Journal of Cancer and Chemotherapy
44
8
出版ステータス出版済み - 8 2017

All Science Journal Classification (ASJC) codes

  • 腫瘍学
  • 癌研究

フィンガープリント

「New treatment options for renal cell carcinoma-efficacy and safety of immune checkpoint inhibitors」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル